Surfactant plays an important role in lung homeostasis and is also involved in maintaining innate immunity within the lung. Lipopolysaccharide (LPS) from gram-negative bacteria is known to elicit acute proinflammatory responses in lung diseases such as acute respiratory distress syndrome and pneumonia, among others. Our previous studies demonstrated that the clinically used, natural surfactant product Survanta inhibited proinflammatory cytokine secretion from LPS-stimulated human alveolar macrophages. Here we investigated the effect of Survanta on mitogen-activated protein (MAP) and IB kinases. Survanta blocked LPS-induced activation of nuclear factor-B, a key regulatory transcription factor involved in cytokine production, by preventing phosphorylation of IB␣, and its subsequent degradation. IB is phosphorylated by specific kinases (IKK) before degradation. Survanta inhibited activity of both ␣ and ␤ subunits of IKK, thereby delaying the phosphorylation of IB. Interestingly, IKK-␣ is predominant in alveolar macrophages, whereas IKK-␤ predominates in monocytes. Survanta also inhibited extracellular signal-regulated kinase and p38 MAP kinase activity induced by LPS. Data are the first to show that surfactant may regulate lung homeostasis in part by inhibiting proinflammatory cytokine production through reduction of IKK and MAP kinase activity.
A major component of innate immunity in the lung is the alveolar macrophage, which responds to microbial challenge by releasing an array of cytokines and chemokines that mediate inflammation. In previous ex vivo studies of from healthy control human alveolar macrophages challenged with endotoxin or Staphylococcus aureus, we observed that surfactant dose-dependently reduced gene expression and protein secretion of inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (4) . Crucial to the activation of many cytokine genes is the transcription factor nuclear factor (NF)-B. We have also demonstrated that surfactant inhibits NF-B activation in the monocytic cell line THP-1 (9) .
The MAP kinases (MAPKs) are a family of enzymes that link cell surface receptors to regulatory targets that include nuclear as well as cytoplasmic proteins (reviewed in Ref. 10) . In blood monocytes and macrophages, lipopolysaccharide (LPS) induces various members of the MAPK family, including p38 and extracellular signal-regulated kinase (ERK). Carter and coworkers have shown that both p38 and ERK are critical for LPS-induced cytokine release in monocytes and alveolar macrophages (11) .
Macrophage inflammatory protein-1␣ (MIP-1) is produced abundantly by alveolar macrophages and is a member of the CC family of chemokines, which attract monocytes, dendritic cells, eosinophils, and lymphocytes to sites of injury (12) . Similar to many inflammatory cytokines and chemokines, MIP-1 is regulated at least in part by NF-B (12) . High levels of MIP-1 are found in bronchoalveolar lavage fluids in many acute and chronic lung diseases (12) . MIP-1 null mice have reduced inflammation in response to viral infections (13) and MIP-1 antibodies abrogate eosinophil influx in animal models of allergic inflammation (reviewed in Ref. 14) . Taken together, these observations suggest a critical role for MIP-1 in the pathology of numerous lung diseases. The effect of surfactant on MIP-1 secretion by human alveolar macrophages has not been previously investigated.
The present study was undertaken to determine the mechanism of signaling disruption by surfactant. We hypothesized that surfactant would inhibit cytokine secretion by disrupting both IKK and MAPK signaling in human alveolar macrophages. The results demonstrate that surfactant targets multiple check points in cell signaling pathways.
Materials and Methods

Reagents
Salmonella typhimurium LPS was obtained from Sigma (St. Louis, MO) and used at 0.5 g/ml for all experiments. Survanta was a gift from Ross Laboratories (Columbus, OH) and used at the previously determined optimum concentration of 1,000 g/ml (4). Survanta is a natural bovine lung extract containing phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins B and C, to which DPPC, palmitic acid, and tripalmitin are added to standardize the composition.
Alveolar Macrophages
Fiberoptic bronchoscopy with bronchoalveolar lavage was performed as previously described (15) . The study population consisted of healthy volunteers, 18-65 yr of age, with no lung disease and on no medication. All volunteers provided written informed consent and the study was approved by the Institutional Review Board of the Cleveland Clinic Foundation. Alveolar macrophages were obtained by adhering cells from bronchoalveolar lavage as previously described (15, 16) . Nonadherent cells were removed by washing. The adherent cell population consisted of Ͼ 99% macrophages. Alveolar macrophages were cultured overnight before in vitro treatment. For each experiment, adhered cells were treated with LPS Ϯ Survanta or left untreated (US).
Preparation of Whole Cell Extracts
After overnight incubation, macrophages were treated with LPS Ϯ Survanta or left untreated for 4 h. Survanta did not adversely affect cell viability as measured by trypan blue dye exclusion and cell adherence. Cells were harvested and whole cell extracts (WCE) prepared as previously described (15) . The protein content of WCE was measured by bicinchoninic acid protein assay method (Pierce, Rockford, IL).
Western Blot Analysis
Cells were washed once with ice-cold phosphate-buffered saline and lysed as described (15) . Protein concentrations were measured and 10 g of the cell lysate was mixed with 1:1 sample buffer, boiled and analyzed on a 10% sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and transferred to Immobilon-P membranes. After blocking membranes, primary antibody to IB␣, p38, or ERK (Santa Cruz Biotechnology, Santa Cruz, CA) or phosphorylated IB␣, ERK, or p38 (Cell Signaling, Beverly, MA) was applied at 1:1,000 dilution for 1 h at room temperature. After secondary antibody application and washing, bands were visualized by enhanced chemiluminescence (Amersham, Arlington Heights, IL).
Construction of GST-IB␣
This plasmid was constructed as previously described (17) . Briefly, amino acids 1-54 were cloned into the Nco I and Xho I site of pGexKG.
Immunoprecipitation and Kinase Assay
Proteins were immunoprecipitated from WCE after preclearance by adding antibody (2 g) and 50 l of A/G Sepharose. After rotation for overnight at 4ЊC, immunoprecipitates were washed with lysis buffer three times and then with kinase buffer (20 mM HEPES-KOH pH7.4, 25 mM ␤-glycerophosphate, 20 mM MgCl 2 ) twice. The kinase assay was performed in a final volume of 20 l of kinase buffer containing 2 g of bacterially purified GST-IB ␣, 20 M of ATP, and 5 mCi [P 32 ] ATP. After incubation for 20 min at 30ЊC, the reaction was stopped by addition of 2ϫ sample buffer. After separation by SDS-PAGE, the gel was dried and autoradiographed.
Preparation of RNA and Analysis
Total RNA was prepared from adhered macrophages by RNAeasy protocol (Qiagen, Valencia, CA). Gene expression was quantified by real time RT-PCR using the ABI prism 7,000 detection system (Taqman; Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. To minimize the error of cross contamination, every sample was done in duplicate using primer/probe sets for a housekeeping gene (GAPDH) and MIP-1␣ (ABI). Threshold cycle (CT) values for genes of interest were normalized to GAPDH and used to calculate the relative quantity of mRNA. Data are expressed as fold change relative to control values.
Analysis of Chemokines
MIP-1␣ was analyzed in duplicate samples of cell-free supernatant fluids from 24-h macrophage cultures by enzyme-linked immunosorbent assay (ELISA; Endogen, Cambridge, MA). Assay sensitivity ranged from 25-1,000 pg/ml, and the coefficient of variation was Ͻ 10%.
Statistical Analysis
Data were analyzed by one-way ANOVA and Student's t test using Prism software (GraphPad, Inc., San Diego, CA). Significance was defined as P р 0.05. Means Ϯ SEM are provided.
Results
MIP-1 Secretion Is Downregulated by Survanta
The effect of Survanta on LPS-stimulated alveolar macrophage MIP-1 production after 24 h was evaluated by ELISA ( Figure 1 ). As expected, treatment with LPS alone increased MIP-1␣ secretion. Simultaneous treatment with Survanta inhibited MIP-1␣ secretion from alveolar macrophages (P ϭ 0.01). To determine whether this inhibitory effect was stimulus specific, granulocyte macrophage colony-stimulating factor (GM-CSF), as an endogenous stimulator, was used. GM-CSF stimulation significantly elevated MIP-1␣ secretion (P ϭ 0. 01). Survanta also decreased GM-CSFinduced MIP-1 ␣ secretion (P ϭ 0.04) (Figure 1 ).
Chemokine Gene Expression Is Downregulated by Survanta
Alveolar macrophage gene expression was quantified by real-time RT-PCR analysis. Alveolar macrophages were isolated and adhered overnight. Cells were then treated with LPS Ϯ Survanta for 24 h and total RNA was isolated. Treatment with LPS alone increased alveolar macrophage gene expression of MIP-1␣, when compared with unstimulated cells. Simultaneous treatment with LPS and Survanta reduced the MIP-1␣ gene expression (P ϭ 0.01; Figure  2 ). Treatment with GM-CSF also increased MIP-1␣ gene expression, although to a lesser extent, when compared with LPS-induced MIP-1␣ gene expression (data not shown).
Survanta Delays IB Degradation
The translocation of NF-B to the nucleus is preceded by the phosphorylation, ubiquitination, and proteolytic degra- dation of IB-␣ (18, 19) . To determine whether Survanta inhibited NF-B activation by blocking IB phosphorylation and degradation, immunoblot analysis of cell lysate from unstimulated cells or from LPS Ϯ Survanta-treated cells was performed. Figure 3 shows that LPS enhanced IB␣ loss (lanes 2-4) in a time-dependent manner. Addition of Survanta delayed the disappearance of IB␣ (compare lanes 2 and 5 with lanes 3 and 6 ). To ascertain that Survanta effects on IB were through phosphorylation, the same blot was immunoprobed using an antibody specific for phosphorylated IB␣ (Figure 3) . LPS induces phosphorylation of IB␣ (lanes 2-4) . LPS induced significant phosphorylation within 45 min and continued until 75 min. Simultaneous addition of Survanta inhibited phosphorylation of the IB protein (compare lane 3 with lane 6). These results suggest that Survanta inhibits phosphorylation of IB and its subsequent degradation. Survanta Inhibits both IKK␣ and ␤-Kinase Activity IB␣ is phosphorylated by IKK complexes (17) . LPS activates IKK␤ in human monocytes, THP-1 cells, and the mouse macrophage cell RAW 264.7 (20) . IKK activity has not been studied in human alveolar macrophages. Because Survanta delayed the phosphorylation of IB, we investigated the effect of Survanta on LPS-induced IKK activity. The kinase complex was immunoprecipitated from unstimulated and LPS Ϯ Survanta-treated cells. Kinase activity was measured in vitro using GST-IB␣ as substrate. Figures 4A  and 4B show that both IKK␣ and IKK␤ were activated by LPS. Unstimulated cells had no basal kinase activity. Addition of Survanta inhibited both IKK␣ and IKK␤ kinase activity. Surprisingly, LPS-stimulated IKK␣ activity in alveolar macrophages is greater than the activity of IKK␤ (Figure 4) . In contrast, studies with the monocytic cell line THP-1 showed that IKK␤ was dominant (21) . Figures 5A and 5B show the time-dependent activation of ERK and p38 kinase and the effect of Survanta on LPSinduced MAPK activation. Phosphorylation of ERK and p38 is almost undetectable in unstimulated condition (lane 1 at left in Figures 5A and 5B). LPS treatment increases both ERK and p38 phosphorylation rapidly in a time-dependent manner (2nd and 4th lane from left). In the presence of Survanta, both the phosphorylation of p38 and ERK is decreased (3rd and 5th lanes from left). 
Survanta Inhibits ERK and p38 Kinase in Human Alveolar Macrophages
Discussion
We have shown that Survanta inhibits LPS-stimulated MIP-1␣ secretion by alveolar macrophages and that this effect is not stimulus-specific because GM-CSF-stimulated MIP-1 was also inhibited. Furthermore, MAPK activation in human alveolar macrophages was reduced by Survanta. Finally, we have shown for the first time that Survanta inhibits both IKK␣ and ␤ activity, thus delaying phosphorylation of IB. Taken together, these observations suggest that surfactant is a potent downregulator of chemokine production and inhibits both NF-B and MAPK pathways. In many airway disorders, inflammation plays a central role and is associated with morbidity and mortality (5-8). Surfactant modulates several inflammatory processes, including cell proliferation and the release of inflammatory mediators (3, 4, 22, 23) . Surfactant deficiencies may contribute to respiratory failure (1, 2) . Previous studies by several groups including ours have shown that synthetic surfactant and several natural surfactant preparations downregulate inflammatory cytokine production by both monocytes and alveolar macrophages (4, 9) . NF-B regulates both innate and adaptive responses and is activated by wide range of stimuli including pathogens, stress signals, and inflammatory cytokines (24) . We previously demonstrated that a synthetic surfactant (Exosurf) blocked NF-B activation in THP-1 cells (9) . Exosurf is no longer used clinically because the two commercially available naturally derived surfactant preparations, Survanta and Infasurf, have greater efficacy in the treatment of neonatal respiratory distress syndrome (25) .
Molecular regulation of inflammatory cytokines is a complex process, and the transcription factor NF-B plays a pivotal role. Sequential phosphorylation, ubiquitination, and degradation of the inhibitory component IB permits NF-B/Rel protein to move to the nucleus (18, 19, 26) . A high molecular mass kinase complex has been described to contain kinase activity specifically for Ser 32 and Ser 36 of IB-␣ (17, 24) . In the present study, we have demonstrated for the first time that surfactant inhibits IB phosphorylation and degradation by blocking both IKK␣ and IKK␤ kinase activity. Furthermore, in contrast to previous studies with the monocytic cell line THP-1 (21), the dominant IKK in human alveolar macrophages appears to be ␣, although ␤, which is much less active, is also reduced by surfactant.
Carter and colleagues (11) have shown that both the ERK and p38 kinase pathways are activated in alveolar macrophages stimulated by LPS and are necessary for optimal cytokine gene transcription. Survanta inhibited ERK and p38 activation. These results suggest that Survanta in part regulates cytokine production in alveolar macrophages by interfering with MAPK signaling.
A recent report has suggested that surfactant associated protein C (SP-C) or a synthetic analog of SP-C binds LPS and prevents LPS binding to mouse macrophages and thus TNF secretion (27) . However, these effects were observed at LPS concentrations of 40 ng/ml. At concentrations higher than 50 ng/ml the ability of synthetic SP-C to neutralize the LPS decreased progressively (27) . In our system we used 500 ng/ml of LPS. We addressed the possibility of LPSsurfactant binding in earlier experiments and found no evidence for binding. We found that cells could be pretreated with LPS for 1 h and then washed and treated with a synthetic surfactant (Exosurf) and TNF secretion was still blocked (4) . Finally, the effects we observed with both Exosurf and Survanta do not appear to be stimulus-specific because Staphylococcus aureus-, interleukin-1-(previous studies) (4), and GM-CSF (present study)-stimulated cytokine secretion were also blocked. Taken together, these observations suggest that the inhibitory effects of surfactant we observed with human alveolar macrophages are not due to surfactant binding to LPS.
In summary, our findings suggest pulmonary surfactant plays a crucial role in maintaining lung homeostasis by serving as an endogenous downregulator of cytokine pro-duction by human alveolar macrophages. Surfactant blocks both chemokine and inflammatory cytokine production by inhibiting IKK activity, which prevents the degradation of IB and subsequent NF-B activation. Furthermore, MAPK signaling was blocked by surfactant. These observations suggest that surfactant, in addition to mechanical benefits to lung function, blocks cellular responses to exogenous stimuli at multiple checkpoints and therefore may be useful in reducing pulmonary inflammatory responses.
